LEADER 01938nam  2200337   450 
001 9910688461303321
005 20230630041156.0
035   $a(CKB)5400000000044762
035   $a(NjHacI)995400000000044762
035   $a(EXLCZ)995400000000044762
100   $a20230630d2020      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aQuinazolinone and Quinazoline Derivatives /$fAli Gamal Al-kaf, editor
210  1$aLondon :$cIntechOpen,$d2020.
215   $a1 online resource (xii, 113 pages)
311   $a1-83880-053-0 
330   $aOne of the problems with modern public health is target searching for new highly effective medicinal preparations. Among those medicinal preparations are the natural and synthetic origins of quinazolinone-4 derivatives. Quinazolinone derivatives are reported to be physiologically and pharmacologically active. They also exhibit a wide range of activities such as anticonvulsant, antiinflammatory, antifungal, antimalarial, and sedative properties. Some of these compounds are identified as drugs used as diuretics, vasodilators, and antihypertensive agents. Moreover, sulfonamide derivatives have been widely used as bacteriostatic agents. Prompted by the above-mentioned facts and in conjunction with our ongoing program on the utility of readily obtainable starting material for the synthesis of heterocyclic systems of biological interest, we have decided to synthesize a series of quinazolinone derivatives having sulfonamide moiety with a potentially wide spectrum of biological responses.
606   $aCyclic compounds
615  0$aCyclic compounds.
676   $a547.6
702   $aAl-kaf$b Ali Gamal
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688461303321
996   $aQuinazolinone and Quinazoline Derivatives$91915736
997   $aUNINA